A1 Journal article (refereed)
Hexyl aminolevulinate, 5‐aminolevulinic acid nanoemulsion, and methyl aminolevulinate in photodynamic therapy of non‐aggressive basal cell carcinomas : A non‐sponsored, randomized, prospective and double‐blinded trial (2020)


Salmivuori, M.; Grönroos, M.; Tani, T.; Pölönen, I.; Räsänen, J.; Annala, L.; Snellman, E.; Neittaanmäki, N. (2020). Hexyl aminolevulinate, 5‐aminolevulinic acid nanoemulsion, and methyl aminolevulinate in photodynamic therapy of non‐aggressive basal cell carcinomas : A non‐sponsored, randomized, prospective and double‐blinded trial. Journal of the European Academy of Dermatology and Venereology, 34 (12), 2781-2788. DOI: 10.1111/jdv.16357


JYU authors or editors


Publication details

All authors or editors: Salmivuori, M.; Grönroos, M.; Tani, T.; Pölönen, I.; Räsänen, J.; Annala, L.; Snellman, E.; Neittaanmäki, N.

Journal or series: Journal of the European Academy of Dermatology and Venereology

ISSN: 0926-9959

eISSN: 1468-3083

Publication year: 2020

Volume: 34

Issue number: 12

Pages range: 2781-2788

Publisher: Wiley-Blackwell

Publication country: United Kingdom

Publication language: English

DOI: https://doi.org/10.1111/jdv.16357

Open Access: Open access publication published in a hybrid channel

Publication is parallel published (JYX): https://jyx.jyu.fi/handle/123456789/68317

Publication is parallel published: https://tuhat.helsinki.fi/ws/portalfiles/portal/134034637/jdv.16357.pdf


Abstract

Background
In the photodynamic therapy (PDT) of non‐aggressive basal cell carcinomas (BCCs), 5‐aminolevulinic acid nanoemulsion (BF‐200ALA) has shown non‐inferior efficacy when compared with methyl aminolevulinate (MAL), a widely used photosensitizer. Hexyl aminolevulinate (HAL) is an interesting alternative photosensitizer. To our knowledge, this is the first study using HAL‐PDT in the treatment of BCCs.

Objectives
To compare the histological clearance, tolerability (pain and post‐treatment reaction), and cosmetic outcome of MAL, BF‐200 ALA, and low‐concentration HAL in the PDT of non‐aggressive BCCs.

Methods
Ninety‐eight histologically verified non‐aggressive BCCs met the inclusion criteria, and 54 patients with 95 lesions completed the study. The lesions were randomized to receive LED‐PDT in two repeated treatments with MAL, BF‐200 ALA, or HAL. Efficacy was assessed both clinically and confirmed histologically at three months by blinded observers. Furthermore, cosmetic outcome, pain, post‐treatment reactions fluorescence, and photobleaching were evaluated.

Results
According to intention‐to‐treat analyses, the histologically confirmed lesion clearance was 93.8% (95% confidence interval [CI] = 79.9–98.3) for MAL, 90.9% (95% CI = 76.4–96.9) for BF‐200 ALA, and 87.9% (95% CI = 72.7–95.2) for HAL, with no differences between the arms (p=0.84). There were no differences between the arms as regards pain, post‐treatment reactions, or cosmetic outcome.

Conclusions
PDT with low‐concentration HAL and BF‐200 ALA have a similar efficacy, tolerability, and cosmetic outcome compared to MAL. HAL is an interesting new option in dermatological PDT, since good efficacy is achieved with a low concentration.


Keywords: photodynamic therapy; carcinomas

Free keywords: non‐aggressive basal cell carcinoma; photodynamic therapy; methyl aminolevulinate; 5‐aminolevulinic acid nanoemulsion; hexyl aminolevulinate


Contributing organizations


Ministry reporting: Yes

Preliminary JUFO rating: 1


Last updated on 2021-02-02 at 09:54